Release Date: February 15, 2024
Expiration Date: February 15, 2025
Activity Overview
This online, on-demand virtual symposium brings together renowned experts in non-small-cell lung cancer (NSCLC). In this educational program, these experts discuss resectable early-stage NSCLC in the context of recent approvals, recommendations, and new clinical trial evidence. They use a case-based format to highlight the coordination of multidisciplinary approaches to treatment and to present new data illustrating the efficacy and safety of these novel strategies.
This educational activity is an archive of the live symposium held on January 27, 2024.
Target Audience
This educational activity is directed toward surgeons, oncologists, and other health care professionals interested in the latest advances in the diagnosis, treatment, and management of lung cancer.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Determine the current and evolving role of mutational testing for personalizing neoadjuvant and adjuvant strategies in the management of resectable non-small-cell lung cancer (NSCLC)
- Explore current approaches and emerging strategies utilizing immune checkpoint inhibitors for the management of resectable NSCLC
- Evaluate emerging strategies in the management of resectable NSCLC including those evaluating ALK tyrosine kinase inhibitors (TKIs) and the potential implication of recent data and ongoing trials
- Identify the safety profile of current and emerging therapies used for resectable NSCLC and multidisciplinary strategies for mitigation of TRAEs in early disease settings
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
